Targeting the major pro-inflammatory interleukin-6-type cytokine receptor gp130 by antagonistic single domain antibodies
In summary, our study has identified and characterized four novel inhibitory high-affinity gp130 nanobodies with potential for use in cytokine-dependent autoimmunity or cancer therapy.
Authors
- Stefan Zielonka (ORCID: https://orcid.org/0000-0002-4649-2843)
- Jens M. Moll (ORCID: https://orcid.org/0000-0003-3508-5828)
- Doreen Manuela Floss (ORCID: https://orcid.org/0000-0002-6675-5313)
- Britta Lipinski (ORCID: https://orcid.org/0000-0001-6476-3523)
- Harald Kolmar (ORCID: https://orcid.org/0000-0002-8210-1993)
- Thuy Tran (ORCID: https://orcid.org/0000-0003-0240-9988)
- Felix Klaus Geyer
- Jürgen Scheller (ORCID: https://orcid.org/0000-0001-9932-1055)
- Silke Pudewell (ORCID: https://orcid.org/0000-0002-4653-7263)
- R. Kunze
- J Heuser
- Inna Dorogobed
- Pia Metzenmacher
Institutions
- Technische Universität Darmstadt (DE)
- Heinrich Heine University Düsseldorf (DE)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-08-15
- DOI
- https://doi.org/10.3389/fimmu.2025.1613004
- Citations
- 1
- Primary Topic
- Monoclonal and Polyclonal Antibodies Research
- Type
- article
- Field-Weighted Citation Impact
- 1.36
Funders
- Deutsche Forschungsgemeinschaft